Atorvastatin indications and usage: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(9 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Atorvastatin#Adult Indications and Dosage]]
{{Atorvastatin}}
{{CMG}}; {{AE}} {{PB}}
 
==Indications and Usage==
 
Atorvastatin is an inhibitor of  [[HMG-CoA reductase]] (statin) indicated as an adjunct therapy to diet to:
 
* Reduce the risk of [[MI]], [[stroke]], revascularization procedures, and [[angina]] in patients without [[CHD]], but with multiple risk factors.
* Reduce the risk of [[MI]] and [[stroke]] in patients with type 2 [[diabetes]] without [[CHD]], but with multiple risk factors.
* Reduce the risk of non-fatal [[MI]], fatal and non-fatal [[stroke]], revascularization procedures, hospitalization for CHF, and [[angina]] in patients with [[CHD]].
* Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed [[dyslipidemia]].
* Reduce elevated TG in patients with [[hypertriglyceridemia]] and primary dysbetalipoproteinemia.
* Reduce total-C and LDL-C in patients with homozygous familial [[hypercholesterolemia]] (HoFH).
* Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial [[hypercholesterolemia]] after failing an adequate trial of diet therapy.
===Limitations of Use===
 
Atorvastatin has not been studied in Fredrickson Types I and V [[dyslipidemia]]s.

Latest revision as of 14:42, 22 July 2014